The serine/threonine phosphatase PP2A regulates a vast portion of the phosphoproteome
including pathways involved in apoptosis, proliferation and DNA damage response and …

The recent development of high throughput compound screening has allowed drug
repurposing to emerge as an effective avenue for discovering novel treatments for cancer …

Tumor cells may adapt to metabolic challenges by alternating between glycolysis and
oxidative phosphorylation (OXPHOS). To target this metabolic plasticity, we combined …

Aberrant protein phosphorylation is one of the hallmarks of cancer cells, and in many cases
a prerequisite to sustain tumor development and progression. Like protein kinases, protein …

Over a century ago, the phenothiazine dye, methylene blue, was discovered to have both
antipsychotic and anti-cancer effects. In the 20th-century, the first phenothiazine …

Metastasis of breast cancer, especially to the brain, is the major cause of mortality. The
inability of anticancer agents to cross the blood-brain-barrier represents a critical challenge …

Drug repositioning is an approach that could accelerate the clinical use of compounds in
different diseases. The goal is to take advantage of the fact that approved drugs have been …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and,
very often, ineffective medical and surgical therapeutic options. The treatment of patients …

Simple Summary Despite significant advancements in neuroblastoma therapy, over half of
the children with high-risk neuroblastoma will suffer disease relapse. Protein phosphatase …

Phosphoprotein phosphatases are of growing interest in the pathophysiology of many
diseases and are often the neglected partner of protein kinases. One family member, PP2A …